NeuroOne restates Q1 2026 results due to $0.5M revenue overstatement
NeuroOne Medical Technologies will amend its Q1 2026 10-Q filing after identifying a $0.5 million revenue recognition error tied to a customer order modification at quarter-end. The company reaffirms its fiscal 2026 product revenue guidance of at least $10.5 million and says ongoing business operations remain unaffected.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day